Metropolis Healthcare Limited (NSE: METROPOLIS) and Vijaya Diagnostic Centre Limited (NSE: VIJAYA) are both listed in the Medical Diagnostic Centres industry. Metropolis Healthcare has a market capitalisation of ₹11,615 Cr and Vijaya Diagnostic Centre ₹15,011 Cr, as of 9 Nov 2026. Their P/E ratios are 60.9 and 86.8 respectively. Return on equity is 13.37% for Metropolis Healthcare and 19.70% for Vijaya Diagnostic Centre. Over one year, Metropolis Healthcare's share price is up 16.6% and Vijaya Diagnostic Centre's is up 49.7%.
| Metric | Metropolis Healthcare | Vijaya Diagnostic Centre |
|---|---|---|
| NSE Symbol | METROPOLIS | VIJAYA |
| BSE Code | 542650 | 543350 |
| Share Price | ₹584.50 | ₹1,480.00 |
| Market Cap | ₹11,615 Cr | ₹15,011 Cr |
| P/E Ratio | 60.9 | 86.8 |
| Return on Equity | 13.37% | 19.70% |
| Return on Assets | 8.36% | 11.02% |
| Dividend Yield | 0.36% | 0.14% |
| Beta (1Y) | 0.84 | 0.83 |
| 1-Year Price Change | +16.6% | +49.7% |
| 3-Month Price Change | +2.1% | +6.3% |
| 52-Week Range | ₹412.25 – ₹609.05 | ₹848.00 – ₹1,593.60 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹497 Cr | ₹255 Cr |
| Quarterly Net Profit | ₹75 Cr | ₹59 Cr |
| Net Margin | 15.2% | 23.3% |
| EPS (Basic, Quarter) | ₹3.64 | ₹5.78 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gy…
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, molecular diagnostics, CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, gastroenterology, nuclear medicine and PET/CT, and MRI-3T services. It also provides health checkups and home sample collection services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
Vijaya Diagnostic Centre has a market capitalisation of ₹15,011 Cr, against ₹11,615 Cr for Metropolis Healthcare as of 9 Nov 2026, about 1.3 times the size by market cap.
Metropolis Healthcare has a P/E of 60.9 and Vijaya Diagnostic Centre a P/E of 86.8 as of 9 Nov 2026.
Metropolis Healthcare has a return on equity of 13.37% and Vijaya Diagnostic Centre 19.70%.
Metropolis Healthcare's share price is up 16.6% over one year and Vijaya Diagnostic Centre's is up 49.7%.
Metropolis Healthcare reported revenue of ₹497 Cr and net profit of ₹75 Cr for Q2 FY27. Vijaya Diagnostic Centre reported revenue of ₹255 Cr and net profit of ₹59 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Health Care Providers and Services > Health Care Services > Medical Diagnostic Centres on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.